Journal d'ophtalmologie clinique et expérimentale
Libre accès

Abstrait

Subconjunctival Bevacizumab Injection in Treatment of Recurrent Pterygium

Hussein Alhammami, Qassim Farhood and Hassanein Shuber

Objective: To determine the clinical effect of subconjunctival injection of bevacizumab in regression or halting growth in patients with recurrent pterygium.
Method and materials: The study was an off-label; 2-dosing, interventional case series involving 20 patients with recurrent pterygium. They received subconjunctival bevacizumab (0.2 ml/2.5 mg). Vascularity and thickness of Pterygium was graded. Size of the pterygium (measured by surface area in cm²) was recorded from baseline to 6 months, after injection. Treatment-related complications and adverse events were reported. The main outcome of measurements was the change in grading, size, vascularity, thickness and color intensity.
Results: 9 males (45%) , 11 females (55%) of 20 patients were conducted in study with a mean age of 50.46 years ± 18.30 (rang 38-70). There was a significant reduction in grading with significant difference in the mean surface area of pterygium at different intervals (P<0.05) and the size of pterygium was reduced. The reduction of color intensity was significant (P=0.031). No significant topical or systemic adverse reactions were recorded.
Conclusions: Subconjunctival bevacizumab injection is useful in management of patients with recurrent pterygium without significant local or systemic adverse effects.